Literature DB >> 21708890

Transient receptor potential vanilloid 1 mediates pain in mice with severe sickle cell disease.

Cheryl A Hillery1, Patrick C Kerstein, Daniel Vilceanu, Marie E Barabas, Dawn Retherford, Amanda M Brandow, Nancy J Wandersee, Cheryl L Stucky.   

Abstract

Pain is the leading cause of emergency department visits, hospitalizations, and daily suffering in individuals with sickle cell disease (SCD). The pathologic mechanisms leading to the perception of pain during acute RBC sickling episodes and development of chronic pain remain poorly understood and ineffectively treated. We provide the first study that explores nociceptor sensitization mechanisms that contribute to pain behavior in mice with severe SCD. Sickle mice exhibit robust behavioral hypersensitivity to mechanical, cold, and heat stimuli. Mechanical hypersensitivity is further exacerbated when hypoxia is used to induce acute sickling. Behavioral mechanical hypersensitivity is mediated in part by enhanced excitability to mechanical stimuli at both primary afferent peripheral terminal and sensory membrane levels. In the present study, inhibition of the capsaicin receptor transient receptor potential vanilloid 1 (TRPV1) with the selective antagonist A-425619 reversed the mechanical sensitization at both primary afferent terminals and isolated somata, and markedly attenuated mechanical behavioral hypersensitivity. In contrast, inhibition of TRPA1 with HC-030031 had no effect on mechanical sensitivity. These results suggest that the TRPV1 receptor contributes to primary afferent mechanical sensitization and a substantial portion of behavioral mechanical hypersensitivity in SCD mice. Therefore, TRPV1-targeted compounds that lack thermoregulatory side effects may provide relief from pain in patients with SCD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21708890      PMCID: PMC3179403          DOI: 10.1182/blood-2010-12-327429

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Windy weather and low humidity are associated with an increased number of hospital admissions for acute pain and sickle cell disease in an urban environment with a maritime temperate climate.

Authors:  Simon Jones; Edward R Duncan; Nikki Thomas; Joan Walters; Moira C Dick; Susan E Height; Adrian D Stephens; Swee Lay Thein; David C Rees
Journal:  Br J Haematol       Date:  2005-11       Impact factor: 6.998

2.  Contributions of central and peripheral TRPV1 receptors to mechanically evoked and spontaneous firing of spinal neurons in inflamed rats.

Authors:  Steve McGaraughty; Katharine L Chu; Brian S Brown; Chang Z Zhu; Chengmin Zhong; Shailen K Joshi; Prisca Honore; Connie R Faltynek; Michael F Jarvis
Journal:  J Neurophysiol       Date:  2008-10-01       Impact factor: 2.714

3.  Nitric oxide activates TRP channels by cysteine S-nitrosylation.

Authors:  Takashi Yoshida; Ryuji Inoue; Takashi Morii; Nobuaki Takahashi; Shinichiro Yamamoto; Yuji Hara; Makoto Tominaga; Shunichi Shimizu; Yoji Sato; Yasuo Mori
Journal:  Nat Chem Biol       Date:  2006-09-24       Impact factor: 15.040

4.  Endothelin-1 potentiates capsaicin-induced TRPV1 currents via the endothelin A receptor.

Authors:  Tim D Plant; Christian Zöllner; Shaaban A Mousa; Alexander Oksche
Journal:  Exp Biol Med (Maywood)       Date:  2006-06

5.  Effects of the transient receptor potential vanilloid 1 antagonist A-425619 on body temperature and thermoregulation in the rat.

Authors:  C Mills; M McMackin; R Jaffe; J Yu; E Zininberg; D Slee; K Gogas; M Bradbury
Journal:  Neuroscience       Date:  2008-07-25       Impact factor: 3.590

6.  Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats.

Authors:  Sonya G Lehto; Rami Tamir; Hong Deng; Lana Klionsky; Rongzhen Kuang; April Le; Doo Lee; Jean-Claude Louis; Ella Magal; Barton H Manning; John Rubino; Sekhar Surapaneni; Nuria Tamayo; Tingrong Wang; Judy Wang; Jue Wang; Weiya Wang; Brad Youngblood; Maosheng Zhang; Dawn Zhu; Mark H Norman; Narender R Gavva
Journal:  J Pharmacol Exp Ther       Date:  2008-04-17       Impact factor: 4.030

Review 7.  The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept.

Authors:  Arpad Szallasi; Daniel N Cortright; Charles A Blum; Samer R Eid
Journal:  Nat Rev Drug Discov       Date:  2007-05       Impact factor: 84.694

8.  Daily assessment of pain in adults with sickle cell disease.

Authors:  Wally R Smith; Lynne T Penberthy; Viktor E Bovbjerg; Donna K McClish; John D Roberts; Bassam Dahman; Imoigele P Aisiku; James L Levenson; Susan D Roseff
Journal:  Ann Intern Med       Date:  2008-01-15       Impact factor: 25.391

9.  Association between wind speed and the occurrence of sickle cell acute painful episodes: results of a case-crossover study.

Authors:  Vikki G Nolan; Yuqing Zhang; Timothy Lash; Paola Sebastiani; Martin H Steinberg
Journal:  Br J Haematol       Date:  2008-08-20       Impact factor: 6.998

10.  HC-030031, a TRPA1 selective antagonist, attenuates inflammatory- and neuropathy-induced mechanical hypersensitivity.

Authors:  Samer R Eid; Eric D Crown; Eric L Moore; Hongyu A Liang; Kar-Chan Choong; Shelley Dima; Darrell A Henze; Stefanie A Kane; Mark O Urban
Journal:  Mol Pain       Date:  2008-10-27       Impact factor: 3.395

View more
  85 in total

1.  Spinal glial activation and oxidative stress are alleviated by treatment with curcumin or coenzyme Q in sickle mice.

Authors:  Yessenia Valverde; Barbara Benson; Mihir Gupta; Kalpna Gupta
Journal:  Haematologica       Date:  2015-11-06       Impact factor: 9.941

2.  Small-molecule nociceptin receptor agonist ameliorates mast cell activation and pain in sickle mice.

Authors:  Derek Vang; Jinny A Paul; Julia Nguyen; Huy Tran; Lucile Vincent; Dennis Yasuda; Nurulain T Zaveri; Kalpna Gupta
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

3.  Dexmedetomidine ameliorates nocifensive behavior in humanized sickle cell mice.

Authors:  Gabriela Calhoun; Li Wang; Luis E F Almeida; Nicholas Kenyon; Nina Afsar; Mehdi Nouraie; Julia C Finkel; Zenaide M N Quezado
Journal:  Eur J Pharmacol       Date:  2015-02-25       Impact factor: 4.432

Review 4.  Neuronal transient receptor potential (TRP) channels and noxious sensory detection in sickle cell disease.

Authors:  Katelyn E Sadler; Cheryl L Stucky
Journal:  Neurosci Lett       Date:  2018-11-30       Impact factor: 3.046

5.  Dissociation between CSD-Evoked Metabolic Perturbations and Meningeal Afferent Activation and Sensitization: Implications for Mechanisms of Migraine Headache Onset.

Authors:  Jun Zhao; Dan Levy
Journal:  J Neurosci       Date:  2018-04-27       Impact factor: 6.167

Review 6.  Targeting novel mechanisms of pain in sickle cell disease.

Authors:  Huy Tran; Mihir Gupta; Kalpna Gupta
Journal:  Blood       Date:  2017-11-30       Impact factor: 22.113

7.  Effect of chronic opioid therapy on pain and survival in a humanized mouse model of sickle cell disease.

Authors:  Huy Tran; Varun Sagi; Waogwende Leonce Song-Naba; Ying Wang; Aditya Mittal; Yann Lamarre; Lei Zhang; Kalpna Gupta
Journal:  Blood Adv       Date:  2019-03-26

Review 8.  Metabolomic and molecular insights into sickle cell disease and innovative therapies.

Authors:  Morayo G Adebiyi; Jeanne M Manalo; Yang Xia
Journal:  Blood Adv       Date:  2019-04-23

9.  Changes in Pain and Psychosocial Functioning and Transition to Chronic Pain in Pediatric Sickle Cell Disease: A Cohort Follow-up Study.

Authors:  Soumitri Sil; Lindsey L Cohen; Nitya Bakshi; Amanda Watt; Morgan Hathaway; Farida Abudulai; Carlton Dampier
Journal:  Clin J Pain       Date:  2020-06       Impact factor: 3.442

Review 10.  Spinal and afferent PKC signaling mechanisms that mediate chronic pain in sickle cell disease.

Authors:  Ying He; Zaijie Jim Wang
Journal:  Neurosci Lett       Date:  2019-04-30       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.